Immunocore Holdings (IMCR) Net Income towards Common Stockholders (2021 - 2026)

Immunocore Holdings has reported Net Income towards Common Stockholders for 6 years, with the latest figure at $13.0 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 160.25% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.6 million (down 27.23% YoY) and the FY2025 annual result came in at -$35.5 million, up 30.48% from the prior year.
• Net Income towards Common Stockholders grew to $13.0 million in Q1 2026 per IMCR's latest filing, from -$30.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $13.0 million in Q1 2026 and troughed at -$30.1 million in Q4 2025.
• A 5-year average of -$10.7 million and a median of -$14.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders jumped 864.24% in 2024, then plunged 102.24% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$29.9 million in 2022, then jumped by 33.95% to -$19.7 million in 2023, then fell by 20.48% to -$23.8 million in 2024, then retreated by 26.46% to -$30.1 million in 2025, then jumped by 143.15% to $13.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $13.0 million, -$30.1 million, and -$196000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.